Zolgensma of Novartis, which passed the Drug Reimbursment Evaluation Committee of the HIRA on the 12th of last month, began negotiations on drug prices to register health insurance benefits. Given that Kymriah of the same company, which has attracted attention as a once-in-a-lifetime drug, succeeded in being reimbursed two months after passing the Drug Reimbursment Evaluation Committee, attention is being paid to whether Kymriah will be able to proceed quickly.

According to the industry on the 3rd, the NHIS and Korea Novartis will start negotiations on the drug price for the SMA treatment Zolgensma on the 25th of last month and proceed for two months until the 25th of next month. Earlier on the 12th of